VYGR

SEC source: 0001104659-20-019455 · a4.xml · derivative · entry 2

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-02-10

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-019455 · a4.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,625

F1 · shares: Consists of shares of common stock issuable under an aggregate of 27,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-019448 · a4.xml · derivative · entry 2

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 162,500 shares

Expires 2030-02-10

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-019448 · a4.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,795

F1 · shares: Consists of shares of common stock issuable under an aggregate of 81,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-008190 · a4.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,522

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · balance_after: Includes 1,097 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan (the "ESPP") on June 28, 2019, and 447 shares of common stock acquired under the ESPP on December 31, 2019.

SEC source: 0001104659-20-008187 · a4.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,545

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-008188 · a4.xml · nonDerivative · entry 1

Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,276

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-19-035998 · a4.xml · derivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-036005 · a4.xml · derivative · entry 1

PAUL STEVEN M · CIK 0001237564 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-036004 · a4.xml · derivative · entry 1

KARSEN PERRY A · CIK 0001260573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its non-employee director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-036003 · a4.xml · derivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-036000 · a4.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-035997 · a4.xml · derivative · entry 1

Higgins Michael J · CIK 0001478521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-035996 · a4.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-035995 · a4.xml · derivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-06-13

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-031178 · a4.xml · derivative · entry 2

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2029-05-20

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F3 · derivative.exercise_date: The vesting commencement date of the option is May 20, 2019. The option vests over four years, with 25% of the shares of Common Stock underlying the option vesting upon the one-year anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable option agreement.

SEC source: 0001104659-19-031178 · a4.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock, par value $0.001 per share, of the Company (the "Common Stock") upon vesting. The vesting commencement date of the RSU award is May 20, 2019. The RSU award vests over three years, with 33.33% of the shares of Common Stock underlying the award vesting upon the one-year anniversary of the vesting commencement date of such award and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable RSU agreement.

SEC source: 0001104659-19-019772 · a4.xml · derivative · entry 2

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,750

Underlying: Common Stock · 168,750 shares

Expires 2029-04-01

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F3 · derivative.exercise_date: The Vesting Commencement Date of the option is April 1, 2019. The option vests over four years, with 25% of the shares of Common Stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable option agreement.

SEC source: 0001104659-19-019772 · a4.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,125

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · balance_after: Includes shares of common stock underlying one or more restricted stock unit ("RSU") awards. Each RSU represents the right to receive one share of common stock, par value $0.001 per share, of the Company (the "Common Stock") upon vesting, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable RSU agreement. The RSU awards vest over three years, with 33.33% of the shares of Common Stock underlying the award vesting upon the one-year anniversary of the vesting commencement date (the "Vesting Commencement Date") of such award and the remainder vesting in equal annual installments thereafter. The Vesting Commencement Date of this RSU award is April 1, 2019.

SEC source: 0001209191-19-019459 · doc4.xml · nonDerivative · entry 1

NEUROCRINE BIOSCIENCES INC · CIK 0000914475 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,179,728

F1 · price: The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 28, 2019 between the reporting person and the issuer.

SEC source: 0001104659-19-002349 · a4.xml · derivative · entry 2

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,500

Underlying: Common Stock · 192,500 shares

Expires 2029-01-11

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002349 · a4.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,250

F1 · shares: Consists of shares of common stock issuable under an aggregate of 96,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002348 · a4.xml · derivative · entry 2

Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-01-11

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002348 · a4.xml · nonDerivative · entry 1

Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,688

F1 · shares: Consists of shares of common stock issuable under an aggregate of 25,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002347 · a4.xml · derivative · entry 2

Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-01-11

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002347 · a4.xml · nonDerivative · entry 1

Ottmer Matthew P. · CIK 0001659870 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002346 · a4.xml · derivative · entry 2

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-01-11

F3 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-19-002346 · a4.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,106

F1 · shares: Consists of shares of common stock issuable under an aggregate of 25,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

F2 · balance_after: Includes 452 shares of common stock acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan (the "ESPP") on June 30, 2018 and 654 shares of common stock acquired under the ESPP on December 31, 2018.

SEC source: 0001104659-18-067413 · a4.xml · derivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2028-11-07

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date, November 7, 2018. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0000899243-18-024774 · doc4.xml · nonDerivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,391,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on September 19, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on September 19, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

SEC source: 0000899243-18-024777 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,391,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on September 19, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on September 19, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

SEC source: 0001104659-18-056499 · a4.xml · nonDerivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 5,000

F1 · ownership.nature: The securities are directly held by the Pierce Family Trust, dated October 13, 1993 (the "Pierce Family Trust"). The Reporting Person's immediate family members are beneficiaries of the Pierce Family Trust. The Reporting Person expressly disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.

SEC source: 0001104659-18-056500 · a4.xml · nonDerivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,588

SEC source: 0001104659-18-053030 · a4.xml · nonDerivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,588

SEC source: 0001104659-18-045813 · a4.xml · derivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2028-07-16

F1 · derivative.exercise_date: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The vesting commencement date (the "Vesting Commencement Date") of the option is July 16, 2018. The option vests over four years, with 25% of the shares of common stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment.

SEC source: 0000899243-18-017586 · doc4.xml · nonDerivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,891,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2017, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2017, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

SEC source: 0000899243-18-017587 · doc4.xml · nonDerivative · entry 1

Third Rock Ventures III, L.P. · CIK 0001569705 · 10% owner

Third Rock Ventures GP III, L.P. · CIK 0001637300 · 10% owner

TRV GP III, LLC · CIK 0001637299 · 10% owner

STARR KEVIN P · CIK 0001192603 · 10% owner

TEPPER ROBERT I · CIK 0001192595 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,891,176

F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures III, L.P. ("TRV III"), Third Rock Ventures GP III, L.P. ("TRV GP III") and TRV GP III, LLC ("TRV GP III LLC"), TRV III distributed on June 20, 2018, for no consideration, 1,500,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP III, the general partner of TRV III, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP III distributed, for no consideration, the Shares it received in the distribution by TRV III to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are directly held by TRV III. The general partner of TRV III is TRV GP III. The general partner of TRV GP III is TRV GP III LLC. The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

SEC source: 0001104659-18-040892 · a4.xml · derivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-040895 · a4.xml · derivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-040894 · a4.xml · derivative · entry 1

Higgins Michael J · CIK 0001478521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-040891 · a4.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-040890 · a4.xml · derivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-040887 · a4.xml · derivative · entry 1

KARSEN PERRY A · CIK 0001260573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-040889 · a4.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-18-023708 · a4.xml · nonDerivative · entry 1

Ravina Bernard · CIK 0001711276 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.04 to $18.61, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-18-020100 · a4.xml · derivative · entry 6

Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 165,584

Underlying: Common Stock · 11,200 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service.

SEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 4

Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.50 to $20.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 3

Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-18-020100 · a4.xml · derivative · entry 5

Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 176,784

Underlying: Common Stock · 19,900 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The option vests over four years, with 53,500 of the shares of common stock underlying the option vesting on 1/1/2018 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service.

SEC source: 0001104659-18-020100 · a4.xml · nonDerivative · entry 2

Henderson Jane · CIK 0001422304 · Sr. V.P. & CFO, Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.30, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., any security holder of Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.